论文部分内容阅读
目的 探讨内皮素 (endothelin ,ET)在肺癌患者血浆、瘤组织中的表达特征及其与病理、临床各因素之间的关系。方法 应用放射免疫法、免疫组化和图像分析技术 ,检测了 6 6例肺癌患者血浆和石蜡标本中ET表达 ,并将所有病例随访至 2年以上。结果 肺癌血浆ET含量明显高于正常对照组 (P <0 .0 1) ,瘤组织中ET阳性表达率高达 73% ,其含量显著高于支气管良性病变 (P <0 .0 1) ,并且分期愈晚、分化愈差、转移范围愈广 ,血浆和瘤组织中ET水平愈高 ,生存率愈低。结论 ET可作为判断肺癌预后的一项有价值指标 ,血浆和瘤组织中ET表达具有一致性 ,在肺癌临床监测中具有同等价值。
Objective To investigate the expression of endothelin (ET) in plasma and tumor tissues of patients with lung cancer and its relationship with pathology and clinical factors. Methods Radioimmunoassay, immunohistochemistry and image analysis were used to detect the expression of ET in plasma and paraffin of 66 patients with lung cancer. All cases were followed up for more than 2 years. Results The plasma ET level in lung cancer was significantly higher than that in the normal control group (P <0.01). The positive rate of ET in tumor tissue was as high as 73%, which was significantly higher than that in benign bronchioles (P <0.01) The later, the poorer the differentiation, the more extensive the metastasis, the higher the ET level in plasma and tumor tissue, the lower the survival rate. Conclusion ET can be used as a valuable index to judge the prognosis of lung cancer. The expression of ET in plasma and tumor tissue is consistent and has the same value in the clinical monitoring of lung cancer.